Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- (-) Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- Low-Value Care
- NPC News
- Pandemic Response
- Patient Centered Formulary & Benefit Design
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- (-) Real-World Evidence
- Regulatory Barriers & Challenges
- (-) Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- (-) Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Display Only
Showing 76 Results
Characterizing health plan evidence review practices: how often, how different, and how comprehensive?
All health care decisions should be evidence-based. Until now, it has been relatively unclear what goes into health plan evidence reviews. How frequently do health plans update their specialty drug…
Health Spending Post-Pandemic: Looking for High Value Beyond the Headlines
NPC Chief Science Officer Dr. Sharon Phares takes a closer look at CMS' national health expenditure report and what their predictions mean for our health care system.
Drug Price Regulation Trade-offs: Real or Imagined?
NPC hosted a panel at AcademyHealth’s National Health Policy Conference to explore the potential risks and unintended consequences of drug price regulation.
The Certainty of Uncertainty in Health Technology Assessment
A new Health Affairs Forefront article from Tufts CEVR examines the potential flaws in how health technology assessments identify and report on uncertainty.
Value Assessment’s ‘Leaky Bucket’ Problem
In Health Affairs Forefront, NPC outlines the challenges in assessing the value of new treatments and proposes a framework and recommendations to ensure patient access to new therapies and continued…
NPC in RealClearPolicy: Price Setting Bill Is No Panacea for Patients
In a commentary for RealClearPolicy, NPC’s John M. O’Brien explains how the drug pricing deal in the Build Back Better Act could create harmful unintended consequences for patient health and the…
Drug Spending Mirrors Spending on Other Health Care Services
Spending on prescription drugs is not an anomaly but rather follows similar patterns as other health care services. Policy proposals that focus narrowly on constraining drug spending are disregarding…
A Healthier Country Means Lower Health Care Spending
The U.S. spends twice as much per person on health care compared to other wealthy countries. While higher U.S. health care prices play a role in this disparity, they are not the only cause. A new NPC…
Avoiding Methodological Faults in Real-World Evidence
Researchers from Brigham and Women’s Hospital, Harvard Medical Center and NPC found that the potential for biased findings in RWE studies increases substantially in the absence of a rigorous and…
Building a Better Evidence Base to Address the Social Determinants of Health
The COVID-19 pandemic has put a spotlight on the pressing need to address social determinants of health (SDOH). NPC's Dr. Dubois examines the gaps within the existing evidence base and how to improve…
What the Data Are Saying on Drug Pricing and Utilization
NPC President and CEO John O'Brien discusses the IQVIA Institute’s new report and takes a closer look at the factors that are driving medication use and health care spending in the United States.
Health Budgets Should Cap Patient Harm
An NPC-RTI study provides guidance on quality metrics and practices that can help decision makers understand which budget cap features have the potential to lessen the impact on patient health and…
AMCP Partnership Forum: Preparing for and Managing Rare Diseases
Stakeholders met virtually for an AMCP Partnership Forum to discuss viable solutions to challenges facing people living with rare disorders, such as affordable and timely access to therapies,…
What’s In Your RWE Evaluation Toolbox?
Real-world evidence (RWE) – information collected from everyday health care experiences – is growing in availability, and many health care decision-makers are interested in understanding and using…
Online Tools to Synthesize Real-World Evidence of Comparative Effectiveness Research to Enhance Formulary Decision Making
The authors describe and compare the features and characteristics of five tools to evaluate real-world evidence studies and add clarity on what the tools provide.
NPC’s Research Informs Policy Conversations
NPC's work was broadly featured in the Journal of Managed Care & Specialty Pharmacy’s 12-part 25th anniversary series featuring “topics of significance” in managed care.
Considering the Future Impact of COVID on Health Spending
AcademyHealth and the National Pharmaceutical Council hosted a salon examining the impact of the pandemic on health spending and resulting challenges to our health care system.
Multi-Criteria Decision Analysis: A Way to Put Patient Concerns Front and Center in Value Assessment?
NHC and NPC released a white paper outlining multi-criteria decision analysis (MCDA), an approach to value assessment that may more holistically address patients’ concerns, experiences and treatment…
Digging Deeper Into Health Spending Data
NPC looks at AHIP's annual “Your Health Care Dollar” analysis, providing proper context and data behind the numbers.
Are ACOs Optimizing Medication Use?
An article in JMCP revisits a 2014 NPC study that surveyed Accountable Care Organizations (ACOs) readiness to optimize medication use. The Reflection article summarizes changes to the ACO policy…